You will be randomly assigned to receive either patritumab deruxtecan or another treatment chosen by your physician

Your physician will select from available treatments including paclitaxel, capecitabine, doxorubicin, or other approved medications

If assigned to patritumab deruxtecan: You will receive the medication through intravenous infusion

If assigned to physician’s choice treatment: The medication will be given either through intravenous infusion or as oral medication, depending on the selected treatment

Your treatment will continue until your disease progresses or you experience unacceptable side effects

Your health status will be regularly evaluated using imaging scans to check if the cancer is responding to treatment

Your overall physical condition will be assessed using a standard performance scale

You will complete quality of life questionnaires about your physical functioning, emotional well-being, and pain levels

Your doctor will monitor you for any side effects throughout the treatment period

Regular health checks will include assessment of any new symptoms or health changes

The study is planned to continue until July 2033

Your participation will last until your disease progresses or you need to stop treatment for other reasons